China SXT Pharmaceuticals IncSXTC
Price$2.96

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.1M-34.6% YoYTTM through 30 Sep 2024
Net Income -$6.2MTTM through 31 Mar 2026
Free Cash Flow -$4MTTM through 31 Mar 2026

Margins

Current
Gross Margin16.2%
EBITDA Margin-619.4%
Operating Margin-1,011.7%
Net Margin-545.2%

Returns

-50.3%ROE
-30.9%ROA

Balance Sheet Health

Debt / Equity0.06x
Current Ratio4.37x
Net Debt-$20Mnet cash position
Cash & Equivalents$28.2M

Quality Metrics

Altman Z-Score-0.59
Piotroski F-Score3 / 9
FCF Margin-353.2%

Multi-Year Trend

Revenue
'23'24'25'26
FY2026: $1.1M
Diluted EPS-$9.13TTM
'19'21'22'23'24'25'26
FY2026: $-9.13

Dividend

No dividend

Capital Allocation

R&D Spend$184.2K
Capex Intensity0.2%

Segment Performance

SegmentRevenueYoYOutlook
Advanced TCMP
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.